ArticleTargeted oncology2025

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors.

Manish R Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.